Cancer Biologics Market Size, Share, and Trends 2025 to 2034

The global cancer biologics market is projected to grow from USD 117.45 billion in 2025 to USD 221.43 billion by 2034, expanding at a CAGR of 7.30%. Growth is driven by rising cancer prevalence, innovative biotechnological developments, and increasing adoption of targeted biologic treatments across major healthcare systems.

Last Updated : July 2025  |  Report Code : 4005  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Biologics Market 

5.1. COVID-19 Landscape: Cancer Biologics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Biologics Market, By Drug Class

8.1. Cancer Biologics Market, by Drug Class

8.1.1 Monoclonal Antibodies

8.1.1.1. Market Revenue and Forecast

8.1.2. Cancer Growth Inhibitors

8.1.2.1. Market Revenue and Forecast

8.1.3. Vaccines

8.1.3.1. Market Revenue and Forecast

8.1.4. Recombinants Proteins

8.1.4.1. Market Revenue and Forecast

8.1.5. CAR-T Cells

8.1.5.1. Market Revenue and Forecast

8.1.6. Angiogenesis Inhibitors

8.1.6.1. Market Revenue and Forecast

8.1.7. Interleukins (IL)

8.1.7.1. Market Revenue and Forecast

8.1.8. Interferons (IFN)

8.1.8.1. Market Revenue and Forecast

8.1.9. Gene Therapy

8.1.9.1. Market Revenue and Forecast

8.1.10. Others

8.1.10.1. Market Revenue and Forecast

Chapter 9. Global Cancer Biologics Market, By Applications

9.1. Cancer Biologics Market, by Applications

9.1.1. Blood Cancer

9.1.1.1. Market Revenue and Forecast

9.1.2. Lung Cancer

9.1.2.1. Market Revenue and Forecast

9.1.3. Breast Cancer

9.1.3.1. Market Revenue and Forecast

9.1.4. Colorectal Cancer

9.1.4.1. Market Revenue and Forecast

9.1.5. Prostate Cancer

9.1.5.1. Market Revenue and Forecast

9.1.6. Gastric Cancer

9.1.6.1. Market Revenue and Forecast

9.1.7. Ovarian Cancer

9.1.7.1. Market Revenue and Forecast

9.1.8. Skin Cancer

9.1.8.1. Market Revenue and Forecast

9.1.9. Liver Cancer

9.1.9.1. Market Revenue and Forecast

9.1.10. Others

9.1.10.1. Market Revenue and Forecast

Chapter 10. Global Cancer Biologics Market, By End use 

10.1. Cancer Biologics Market, by End use

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast

10.1.2. Cancer Center

10.1.2.1. Market Revenue and Forecast

10.1.3. Academics & Research Institutes

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Cancer Biologics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Class

11.1.2. Market Revenue and Forecast, by Applications

11.1.3. Market Revenue and Forecast, by End use

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Class

11.1.4.2. Market Revenue and Forecast, by Applications

11.1.4.3. Market Revenue and Forecast, by End use

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Class

11.1.5.2. Market Revenue and Forecast, by Applications

11.1.5.3. Market Revenue and Forecast, by End use

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Class

11.2.2. Market Revenue and Forecast, by Applications

11.2.3. Market Revenue and Forecast, by End use

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Class

11.2.4.2. Market Revenue and Forecast, by Applications

11.2.4.3. Market Revenue and Forecast, by End use

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Class

11.2.5.2. Market Revenue and Forecast, by Applications

11.2.5.3. Market Revenue and Forecast, by End use

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Class

11.2.6.2. Market Revenue and Forecast, by Applications

11.2.6.3. Market Revenue and Forecast, by End use

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Class

11.2.7.2. Market Revenue and Forecast, by Applications

11.2.7.3. Market Revenue and Forecast, by End use

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Class

11.3.2. Market Revenue and Forecast, by Applications

11.3.3. Market Revenue and Forecast, by End use

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Class

11.3.4.2. Market Revenue and Forecast, by Applications

11.3.4.3. Market Revenue and Forecast, by End use

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Class

11.3.5.2. Market Revenue and Forecast, by Applications

11.3.5.3. Market Revenue and Forecast, by End use

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Class

11.3.6.2. Market Revenue and Forecast, by Applications

11.3.6.3. Market Revenue and Forecast, by End use

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Class

11.3.7.2. Market Revenue and Forecast, by Applications

11.3.7.3. Market Revenue and Forecast, by End use

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Class

11.4.2. Market Revenue and Forecast, by Applications

11.4.3. Market Revenue and Forecast, by End use

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Class

11.4.4.2. Market Revenue and Forecast, by Applications

11.4.4.3. Market Revenue and Forecast, by End use

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Class

11.4.5.2. Market Revenue and Forecast, by Applications

11.4.5.3. Market Revenue and Forecast, by End use

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Class

11.4.6.2. Market Revenue and Forecast, by Applications

11.4.6.3. Market Revenue and Forecast, by End use

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Class

11.4.7.2. Market Revenue and Forecast, by Applications

11.4.7.3. Market Revenue and Forecast, by End use

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Class

11.5.2. Market Revenue and Forecast, by Applications

11.5.3. Market Revenue and Forecast, by End use

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Class

11.5.4.2. Market Revenue and Forecast, by Applications

11.5.4.3. Market Revenue and Forecast, by End use

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Class

11.5.5.2. Market Revenue and Forecast, by Applications

11.5.5.3. Market Revenue and Forecast, by End use

Chapter 12. Company Profiles

12.1. Abbott

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Angel

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Amgen, Inc

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. AstraZeneca

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. BioNTech

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bristol-Mayer Squibb Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Dr. Reddy's Laboratories

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Duality Biologics

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Eli Lilly and Company

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. F.Hoffmann-La Roche Ltd.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global cancer biologics market size is expected to increase USD 221.43 billion by 2034 from USD 109.46 billion in 2024.

The global cancer biologics market will register growth rate of 7.30% between 2025 and 2034.

The major players operating in the cancer biologics market are Abbott, Angel, Amgen, Inc, AstraZeneca, BioNTech, Bristol-Mayer Squibb Company, Dr. Reddy's Laboratories, Duality Biologics, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd, GSK plc., Ichnos Sciences Inc, Johnson & Johnson Services, Inc, Pfizer, Inc, TFC Therapeutics, and Others.

The driving factors of the cancer biologics market are the increasing incidence of cancer and the growing advancement in biotechnology.

North America region will lead the global cancer biologics market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client